SCHEMBL18406355

SCHEMBL18406355

CC(C)OC(=O)/C=C/C(=O)OCCN(C)C(=O)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 5/20 0.42
ALDH1A1 P00352 1/20 0.36
ATM Q13315 1/20 0.35
TXNRD1 Q16881 1/20 0.34
CA12 O43570 1/20 0.32
AKR1B10 O60218 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
AKR1B1 P15121 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
XPO1 O14980 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18412206 0.89 ATM (0.42) HCAR2ALDH1A1ATMTXNRD1CHRNB2
SCHEMBL18406339 0.84 HCAR2 (0.47) HCAR2ALDH1A1ATMTXNRD1CA12
SCHEMBL18406343 0.83 HCAR2 (0.46) HCAR2ALDH1A1ATMTXNRD1CA12
SCHEMBL18406342 0.83 HCAR2 (0.42) HCAR2ALDH1A1ATMTXNRD1CHRNB2
SCHEMBL18364205 0.82 HCAR2 (0.44) HCAR2ALDH1A1ATMTXNRD1CA12
SCHEMBL18406358 0.82 HCAR2 (0.44) HCAR2ALDH1A1ATMTXNRD1CA12
SCHEMBL18353127 0.81 CHRNB2 (0.42) HCAR2ALDH1A1ATMTXNRD1CHRNB2
SCHEMBL3517017 0.81 HCAR2 (0.50) HCAR2ALDH1A1ATMCA12AKR1B10
SCHEMBL18406351 0.81 HCAR2 (0.43) HCAR2ALDH1A1ATMTXNRD1CA12
SCHEMBL18364195 0.77 HCAR2 (0.40) HCAR2ALDH1A1ATMTXNRD1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170022149-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2017-01-26 US disclosed
US-20170022149-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE Nguyen, Mark Quang (US) 2017-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022149-A1 FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE FH, FPGS, APC HCAR2 290/4885ALDH1A1 1949/4885ATM 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.